Q1 2021: Kuehne+Nagel marks a strong start to 2021

• High demand for Sea and Air Logistics services
• European Road Logistics volumes recovered and stable
• Contract Logistics profits rise on effects of concluded restructuring

Schindellegi / CH, April 26, 2021 – Kuehne+Nagel’s start to the 2021 business year was marked by strong demand in transport services, especially for pharma and e-commerce fulfillment. Kuehne+Nagel achieved an excellent result in this environment: net turnover of over CHF 6.0 billion, EBIT of CHF 431 million, and earnings for the period of CHF 318 million were all significantly higher year-on-year.

Dr. Detlef Trefzger, CEO of Kuehne + Nagel International AG, says: “Exactly one year ago when we were still at the beginning of the pandemic, we decided to commit to our proven strategy. Upon reflection, we are assured that we chose the correct path: in the first quarter of 2021, we were well-prepared to serve our customers’ robust demand for high-quality logistics services despite the tense market environment. We expect this environment to remain challenging for the remainder of another atypical year.”

Sea Logistics

The positive profit trend reversal in Sea Logistics, already noted in the second half of 2020, continued in the first quarter of 2021. Kuehne+Nagel delivered intensified service to meet exceedingly high customer demands, particularly in the US, in an environment of limited container capacities, reduced terminal productivity, and increasing demand. Volume growth was particularly strong in the consumer goods segment.

Container volumes in the first quarter of 2021 were up 2% year-on-year at 1.1 million TEU, despite a decline in recyclables demand. The unit’s net turnover was nearly CHF 2.4 billion and EBIT CHF 206 million. The conversion rate reached a record high of 42.7%.

With a new alert feature in the online Seaexplorer platform, Sea Logistics customers are informed promptly about irregularities in container transport. This transparency proved particularly helpful to remedy disrupted supply chains during the Suez Canal incident in March.

Air Logistics

Air Logistics saw a return to trade volume growth in the first quarter of 2021, the first time in more than two years. This was contrasted by limited global freight capacities. Kuehne+Nagel’s expertise in dealing with this bottleneck was particularly crucial for the transport of pharma and essential goods.

Airfreight volumes developed positively, reaching 433,000 tonnes in the first quarter of 2021 (16% year-on-year). Combined with strong yields, net turnover improved to CHF 1.7 billion and EBIT to CHF 163 million. The conversion rate was 40.5%.

Further progress was made in the digitalization and automation of Air Logistics processes (eTouch). This development was particularly advanced in the booking processes, invoicing, and documentation.

Road Logistics

In Road Logistics, the first quarter of 2021 was characterized by a significant increase in consignment numbers and a return of European national transport capacities to prior-year levels. After a weak start, UK transport demand recorded a noticeable recovery throughout the remainder of the quarter.

The unit’s net turnover of CHF 870 million in the first quarter of 2021 was at the previous year’s level; however, EBIT of CHF 24 million improved by 41.2% year-on-year.

Originally designed for Asia, the online booking platform for Road Logistics, eTrucknow, was successfully launched in Australia and Russia in the first quarter of 2021.

Contract Logistics

In the first quarter of 2021, Contract Logistics returned to organic growth of 4%, in line with the market. As a result of the divestment of part of the UK business as of January 1, 2021, turnover declined in the first quarter of 2021.

The unit’s net turnover of over CHF 1.1 billion was 9.3% below the previous year; EBIT, however, increased by 123.5% to CHF 38 million.

The pharma business and e-commerce fulfillment activities again had a positive impact. In March, the business unit entered into a strategic partnership with Jointown, the largest non-state pharmaceutical distributor in China.